Form D Report: Adjuvance Technologies $7.00 million Financing. Christopher Frigon Released Nov 14 SEC Filing

Biotechnology Adjuvance Technologies Inc. - Christopher Frigon

Adjuvance Technologies Financing

Adjuvance Technologies Inc., Corporation just submitted form D announcing $7.00 million debt financing. The date of first sale was 2015-08-06. Adjuvance Technologies was able to finance itself with $2.72 million so far. That is 38.82% of the offering. The total private offering amount was $7.00 million. The fundraising form was filed on 2016-11-14. The reason for the financing was: unspecified. The fundraising still has about $4.28 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.

Adjuvance Technologies is based in New York. The filler’s business is Biotechnology. The form D was submitted by Christopher Frigon Corporate Secretary. The company was incorporated more than five years ago. The filler’s address is: 16 West 22Nd Street, 6Th Floor, New York, Ny, New York, 10010. Jeffrey Gardner is the related person in the form and it has address: 116 West 22Nd Street, #1, New York, Ny, New York, 10011. Link to Adjuvance Technologies Filing: 000165278616000003.

Analysis of Adjuvance Technologies Offering

On average, startups in the Biotechnology sector, sell 73.77% of the total offering amount. Adjuvance Technologies sold 38.82% of the offering. The fundraising is still open. The average investment floor size for companies in the Biotechnology industry is $3.08 million. The offering was 11.76% smaller than the average of $3.08 million. Of course this should not be interpreted as negative. Firms raise funds for a variety of reasons and needs. The minimum investment for this financing is set at $25000. If you know more about the reasons for the fundraising, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Adjuvance Technologies Also

The Form D signed by Christopher Frigon might help Adjuvance Technologies Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment